Evidence map›Paper›PMID 41251391›Full record

ArticleAnalytical chemistry2025

High-Efficiency Analytical Protein A Columns for High Sensitivity Monoclonal Antibody Titer Analysis.

Beatrice Muriithi, Fabrice Gritti, Martin Gilar, Yeliz Sarisozen, Matthew Lauber, Kevin Wyndham

Abstract read
In one paragraph

Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Beatrice MuriithiWaters Corporation, 34 Maple Street, Milford, Massachusetts 01757, USA.ORCID 0009-0002-4176-9812
Fabrice GrittiWaters Corporation, 34 Maple Street, Milford, Massachusetts 01757, USA.ORCID 0000-0003-1023-9050
Martin GilarWaters Corporation, 34 Maple Street, Milford, Massachusetts 01757, USA.
Yeliz SarisozenWaters Corporation, 34 Maple Street, Milford, Massachusetts 01757, USA.
Matthew LauberWaters Corporation, 34 Maple Street, Milford, Massachusetts 01757, USA.
Kevin WyndhamWaters Corporation, 34 Maple Street, Milford, Massachusetts 01757, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The quantification of monoclonal antibodies (mAbs) using analytical Protein A affinity chromatography HPLC columns with porous particles of 20 μm or larger diameters is a common method in bioprocessing analytics. The limitations of this method are long run times, relatively broad peaks, and low sensitivity. To address this, we developed an analytical Protein A column packed with 3.5 μm nonporous particles in organosilica-modified hardware, designed to minimize nonspecific binding of mAbs and enable rapid, reproducible, and sensitive measurements. Experimental and theoretical results show that smaller, nonporous particles reduce analyte axial dispersion and mass transfer-related band broadening. This leads to three times narrower peaks and greater peak heights compared to those obtained with 20 μm fully porous particles. Although the column with 3.5 μm nonporous particles has more than ten times less surface area and 50% less Protein A density, its dynamic binding capacity is 62% at 10% breakthrough compared to a column of the same size packed with 20 μm porous particles. This implies that not all of the available surface area or ligand capacity is accessible for binding for the fully porous particles. Both columns demonstrated greater than 98% recovery and a low carryover of less than 0.3% for the analytical scale mass load. The use of 3.5 μm nonporous particles improves the speed, sensitivity, and efficiency of analytical Protein A chromatography, making it applicable to high-throughput bioprocess monitoring.

Indexed as

Antibodies, MonoclonalChromatography, AffinityStaphylococcal Protein AAnimalsChromatography, High Pressure LiquidParticle SizePorosityAntibodies, MonoclonalStaphylococcal Protein A

Identifiers

PMID41251391
PMCPMC12874220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.